Mani (7730) · InitiativeFirst stated

Strengthening the European Ophthalmic Sales Structure Through an Investment in iRIS

First written in FY2026-H1. . Latest entry: FY2026-H1.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Strengthening overseas and global sales and business developmentA theme 265 companies write about · 1 as a headwind · 290 as a tailwind

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 183 companies compared. The sentences above are computed from all 183.Comparing 200 of the theme's 293 threads.

Full recordFilings, disclosures and news, newest first

FY2026-H1First statedAnnual report
「On 22 December 2025, the company entered into an equity transfer agreement to acquire a 36.67% interest in iRIS from a major shareholder of the German ophthalmic product distributor, making iRIS an equity-method affiliate. Through this investment, the company will position Europe as one of its priority regions for further growth in its Surgical business, centered on ophthalmic products, and will strengthen its sales structure centered on iRIS.」
The company disclosed a new initiative to strengthen its European sales structure for ophthalmic products centered on German ophthalmic distributor iRIS through a 36.67% investment in the company.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Mani's next results are scheduled for 2026-10-15. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.